Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA f... ( LA JOLLA Calif. July 23 /- Duska ...)

Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment

Date:7/23/2008

LA JOLLA, Calif., July 23 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S. Food and Drug Administration's (the "FDA") Division of Cardiovascular and Renal Products.

Based on recent communications with the FDA, including a face-to-face meeting held on April 16, 2008, Duska believes that the proposed single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with paroxysmal supraventricular tachycardia (PSVT) should be sufficient to demonstrate clinical safety and efficacy. The proposed primary endpoint of the study is dose-dependent conversion of PSVT to normal sinus rhythm. The FDA has expressed willingness to review and comment on the proposed trial design according to the Special Protocol Assessment (SPA) procedure.

PSVT is a rapid regular heart rate originating in the atria. It has been estimated that there are 89,000 new cases of PSVT per year in the United States alone. PSVT is one of the most common cardiac arrhythmias.

Duska has already compiled clinical data on the safety and efficacy of adenosine triphosphate (ATP), which is the active pharmaceutical ingredient in ATPace(TM), in the treatment of patients with PSVT. In addition, Duska has its own safety database on ATPace(TM), which was obtained in Phase 1 and 2 clinical trials. Based on these data, Duska believes that upon successful completion of the proposed Phase 3 trial, it would have all the clinical data necessary to support the filing of the NDA for ATPace(TM) under section 505(b)(2), the drafting of which has already commenced.

Dr. James Kuo, Duska's Chairman and CEO, said, "After our recent interactions with the FDA, I believe we have a clear plan to acquire all the data that would be necessary to support the filing of a NDA for ATPace(TM)
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent

Post Your Comments:

Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA f...( LA JOLLA Calif. July 23 /- Duska ...)